Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CORCEPT THERAPEUTICS INCORPORATED

(CORT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Corcept Therapeutics Incorporated : Announces Settlement Deal for Patent Dispute With Sun Pharmaceutical Industries

06/15/2021 | 09:45am EDT


ę MT Newswires 2021
All news about CORCEPT THERAPEUTICS INCORPORATED
09/20CORCEPT THERAPEUTICS INCORPORATED : Positive Results Presented at ESMO 2021 From Randomize..
AQ
09/17CORCEPT THERAPEUTICS INCORPORATED : Positive Results Presented at ESMO 2021 From Randomize..
AQ
09/17Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of R..
CI
09/16INSIDER SELL : Corcept Therapeutics
MT
09/10CORCEPT THERAPEUTICS INCORPORATED : Announces Presentation of Positive Results From Random..
AQ
09/09Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase ..
GL
09/09Corcept Therapeutics Incorporated Announces Presentation of Positive Results from Rando..
CI
09/03INSIDER SELL : Corcept Therapeutics
MT
08/13CORCEPT THERAPEUTICS INCORPORATED : WILLIAM GUYER TO JOIN CORCEPT AS CHIEF DEVELOPMENT OFF..
PU
08/13Corcept Therapeutics Incorporated Announces Separation of Andreas Grauer as Chief Medic..
CI
More news
Analyst Recommendations on CORCEPT THERAPEUTICS INCORPORATED
More recommendations
Financials (USD)
Sales 2021 373 M - -
Net income 2021 108 M - -
Net Debt 2021 - - -
P/E ratio 2021 23,8x
Yield 2021 -
Capitalization 2 366 M 2 366 M -
Capi. / Sales 2021 6,35x
Capi. / Sales 2022 5,53x
Nbr of Employees 236
Free-Float 83,3%
Chart CORCEPT THERAPEUTICS INCORPORATED
Duration : Period :
Corcept Therapeutics Incorporated Technical Analysis Chart | CORT | US2183521028 | MarketScreener
Technical analysis trends CORCEPT THERAPEUTICS INCORPORATED
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Last Close Price 20,41 $
Average target price 25,25 $
Spread / Average Target 23,7%
EPS Revisions
Managers and Directors
Joseph K. Belanoff President, Chief Executive Officer & Director
Atabak Mokari Chief Financial Officer
James N. Wilson Chairman
Hazel Hunt Chief Scientific Officer
David L. Mahoney Independent Director
Sector and Competitors
1st jan.Capi. (M$)
CORCEPT THERAPEUTICS INCORPORATED-21.60%2 366
JOHNSON & JOHNSON4.09%431 227
ROCHE HOLDING AG10.52%321 941
PFIZER, INC.19.23%247 816
NOVO NORDISK A/S48.69%229 255
ELI LILLY AND COMPANY37.20%210 000